Bio + Health

Greg Verdine, Bio + Health Venture Partner

Vineeta Agarwala and Jorge Conde Posted July 20, 2023

As we strive to find and support the most ambitious life sciences founders, we also work to connect these founders with exceptional advisors who have traveled the journey before. Builders who have stood up impactful platform biotech companies and put new drugs into the clinic. Leaders who have earned the ability to see around “biological corners.” Mentors who can predict pitfalls of a new modality, but also–just as importantly–share in the optimism needed to try something completely new to solve an unmet patient need. Among such people, few shine as brightly as Greg Verdine.

We are thrilled to welcome Greg to the a16z Bio + Health team as a Venture Partner.

Greg is a unique scientific leader in both the academic and biotech worlds, a pioneer of new therapeutic modalities, and a serial entrepreneur. As you’ll hear directly from Greg in the podcast linked above, his career began from humble roots–an uncanny ability to tinker and an insatiable drive to solve the hardest problems available led him to take aim at targets that had previously been deemed “undruggable.”

Over three decades as Erving Professor of Chemistry at Harvard University and Harvard Medical School (he is now Emeritus faculty), Greg seamlessly toggled between the worlds of basic and applied scientific discovery. His lab elucidated fundamental mechanisms of epigenetic DNA modification and DNA damage repair–and also invented entirely new drug modalities, such as stapled peptides. Greg embraced the challenge of translating academic discoveries into real-world medicines, leading him to found or co-found a number of biotech companies: Enanta Pharmaceuticals (ENTA), Gloucester Pharmaceuticals (acquired by Celgene), Tokai Pharmaceuticals (TKAI), Wave Life Sciences (WVE), Eleven Biotherapeutics (EBIO), Warp Drive Bio (acquired by Revolution Medicines), Aileron Therapeutics, FogPharma, and Lifemine Therapeutics (where he is presently co-founder/CEO). These companies have succeeded in achieving FDA approval for three marketed drugs, and have more than 10 drugs across multiple modalities currently in development.

With a founder’s mindset and a wealth of experience navigating the discovery and development of novel therapeutics, Greg is an invaluable thought partner in biotech. We’re so excited to work together, alongside our portfolio founders, to scale our collective impact on the entire ecosystem.

Want More a16z Bio + Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Learn More
Recommended For You
General

The Lighthouse Playbook

David Booth
General

The Case for Scaling Venture

Erik Torenberg
General

Death of Software. Nah.

Steven Sinofsky

Want More Bio+Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Sign Up On Substack

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.